Navigation Links
Patients' underlying health linked to worse outcomes for melanoma, U-M study finds
Date:8/30/2011

ANN ARBOR, Mich. It's not how old but how frail patients are that can predict how well they will fare after a melanoma diagnosis. In fact, young patients in poor health may have worse outcomes than older patients in good shape.

A new study from the University of Michigan Comprehensive Cancer Center finds that patients with decreased core muscle density were more likely to see their cancer spread to distant parts of the body.

These findings may also support the idea that the patient's biological response to a tumor is important in controlling the spread of melanoma. Patients whose systems are less able to mount a response may be more prone to their cancer spreading.

The researchers believe that identifying those patients who are at higher risk of poor outcomes could impact treatment decisions, including the success of new immunotherapy drugs. And potentially, if this degenerative muscle loss, called sarcopenia, can be reversed, patients might have better outcomes.

The study, which appears online in Annals of Surgical Oncology, looked at 101 patients treated for stage III melanoma at the U-M Comprehensive Cancer Center. Researchers examined CT scans for each patient to measure the area and density of a core muscle called the psoas, which runs along both sides of the spine.

They found that patients with lower muscle density had significantly higher rates of their cancer returning regardless of factors such as the size of the tumor or the patient's age. Every 10 units of decreased muscle density translated to a 28 percent increase in recurrence. In addition, frailer patients had more complications from surgery to remove their cancerous lymph nodes.

Research has previously linked older age to worse outcomes in melanoma. These new results distinguish that it's the underlying vitality of the patient, not age, that really matters.

Many studies have looked at ways to reverse sarcopenia by focusing on diet and exercise.

"The big question is if we could reverse sarcopenia through better nutrition and exercise, would that lead to a decreased risk of recurrence in those patients?" says lead study author Michael S. Sabel, M.D., associate professor of surgery at the U-M Medical School.

In addition, researchers hope this information will help explain the limited success of new immunotherapy or cancer vaccine treatments.

"The data suggests that frailer patients may be less likely to respond to these forms of therapy. It is very possible that prior trials of vaccines or other immune therapies that didn't show an effect would have shown an effect if we had weeded out the patients unlikely to respond to therapy," Sabel says.

Researchers plan next to look at CT scans from patients treated in these trials to analyze whether the treatments were more effective in patients without sarcopenia.

Melanoma statistics: 68,130 Americans will be diagnosed with melanoma this year and 8,700 will die from the disease, according to the American Cancer Society


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Transcatheter aortic valve implantation with the Edwards valve prosthesis in patients with low
2. What do patients receiving optimal medical therapy after a heart attack die from?
3. Potential benefits of remote follow-up of ICD patients
4. Clinical outcomes in PCI patients given sirolimus-eluting and everolimus-eluting stents
5. Patients are living longer with ICDs, but pacing impacts survival rates
6. Temporary ER staff poses increased safety risk to patients
7. Uninsured trauma patients are more likely to use the ED for follow-up care
8. Dialysis Patients Unprepared for Disasters, Study Contends
9. Achieving realistic physical activity goals benefits RA patients
10. Bone marrow transplantation may increase cancer resistance in patients
11. Clinical trial shows benefit to adding avastin to neoadjuvant chemotherapy in breast cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Rassouli, dentist in ... cognitive decline. According to the research, which was published in the “Journal of the ... decline, and about 5.4 million Americans have Alzheimer’s disease. The study found that dental ...
(Date:5/2/2016)... Boston, MA (PRWEB) , ... May 02, 2016 , ... ... and tips when trying to conceive. , “If you are ready to ... Dr. Mache Seibel. “My book, HealthChequesTM: Journal Babies is your Personal Conception & ...
(Date:5/2/2016)... ... ... Kulbersh of Carolina Facial Plastics isn’t surprised that Charlotte, NC, the city where he and ... Cities with the Highest Plastic Rates .” The other cities that made the list ... a survey by RealSelf and combining that data with the number of board-certified ...
(Date:5/2/2016)... Beach, FL (PRWEB) , ... May 02, 2016 , ... ... to great pain and suffering. With no cure, most patients must deal with prescription ... a free coupon card, allowing up to 75% savings at the pharmacy on many ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... which includes amniotic fluid/“stem cells” and Platelet Rich Plasma (PRP) injections. “These are ... said Dr. James Baranski, D.C., of Advanced Spine & Sport Medical. “We are ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... -- The blood testing market in China ... and The Freedonia Group in a recent report.  The ... healthcare research firm said that China ... and in improving testing at the provincial level.   The ... Blood Testing Market in China , which utilized ...
(Date:4/28/2016)... 2016   Acsis , a leading provider of ... market research and advisory firm IDC has named it ... Worldwide Pharmaceutical Track and Trace Software 2016 Vendor Assessment ... assessment of the capabilities and business strategies of 10 ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... 2016 Im ... Zürich gab Strekin AG den Start einer ... Erhaltung des Resthörvermögens von Patienten, denen ein ... umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan Patienten ... während der Operation direkt ins Mittelohr verabreicht. ...
Breaking Medicine Technology: